Therapeutic uses for vegfr1 antibodies
AssigneeEli Lilly and Company
InventorsZHONGHUA QI, MATTHEW DOUGLAS BREYER, LING LIU
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of using VEGFR1 antibodies for the treatment of chronic kidney disease.
Claims14
A method of treating chronic kidney disease in a patient, comprising administering to a patient in need thereof, an effective amount of a VEGFR1 antibody, wherein the VEGFR1 antibody is an antibody comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises the complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3, and the HCVR comprises the CDRs HCDR1, HCDR2, and HCDR3, wherein the LCDR1 is the polypeptide consisting of the amino acid sequence of RASQSVSSSYLA (SEQ ID NO:
- 8), the LCDR2 is the polypeptide consisting of the amino acid sequence of GASSRAT (SEQ ID NO:
- 9), the LCDR3 is the polypeptide consisting of the amino acid sequence of QQYGSSPLT (SEQ ID NO:
- 10), the HCDR1 is the polypeptide consisting of the amino acid sequence of GFAFSSYGMH (SEQ ID NO:
- 2), the HCDR2 is the polypeptide consisting of the amino acid sequence of VIWYDGSNKYYADSVRG (SEQ ID NO:
- 3), and the HCDR3 is the polypeptide consisting of the amino acid sequence of DHYGSGVHHYFYYGLDV (SEQ ID NO:
- 4).
A method of decreasing proteinuria in a patient having chronic kidney disease, comprising administering to a patient in need thereof, an effective amount of a VEGFR1 antibody, wherein the VEGFR1 antibody is an antibody comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises the complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3, and the HCVR comprises the CDRs HCDR1, HCDR2, and HCDR3, wherein the LCDR1 is the polypeptide consisting of the amino acid sequence of RASQSVSSSYLA (SEQ ID NO:
- 8), the LCDR2 is the polypeptide consisting of the amino acid sequence of GASSRAT (SEQ ID NO:
- 9), the LCDR3 is the polypeptide consisting of the amino acid sequence of QQYGSSPLT (SEQ ID NO:
- 10), the HCDR1 is the polypeptide consisting of the amino acid sequence of GFAFSSYGMH (SEQ ID NO:
- 2), the HCDR2 is the polypeptide consisting of the amino acid sequence of VIWYDGSNKYYADSVRG (SEQ ID NO:
- 3), and the HCDR3 is the polypeptide consisting of the amino acid sequence of DHYGSGVHHYFYYGLDV (SEQ ID NO:
- 4).
A method of decreasing albuminuria in a patient having chronic kidney disease, comprising administering to a patient in need thereof, an effective amount of a VEGFR1 antibody, wherein the VEGFR1 antibody is an antibody comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises the complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3, and the HCVR comprises the CDRs HCDR1, HCDR2, and HCDR3, wherein the LCDR1 is the polypeptide consisting of the amino acid sequence of RASQSVSSSYLA (SEQ ID NO:
- 8), the LCDR2 is the polypeptide consisting of the amino acid sequence of GASSRAT (SEQ ID NO:
- 9), the LCDR3 is the polypeptide consisting of the amino acid sequence of QQYGSSPLT (SEQ ID NO:
- 10), the HCDR1 is the polypeptide consisting of the amino acid sequence of GFAFSSYGMH (SEQ ID NO:
- 2), the HCDR2 is the polypeptide consisting of the amino acid sequence of VIWYDGSNKYYADSVRG (SEQ ID NO:
- 3), and the HCDR3 is the polypeptide consisting of the amino acid sequence of DHYGSGVHHYFYYGLDV (SEQ ID NO:
- 4).
A method of protecting against renal histopathological lesions in a patient, comprising administering to a patient in need thereof, an effective amount of a VEGFR1 antibody, wherein the VEGFR1 antibody is an antibody comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises the complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3, and the HCVR comprises the CDRs HCDR1, HCDR2, and HCDR3, wherein the LCDR1 is the polypeptide consisting of the amino acid sequence of RASQSVSSSYLA (SEQ ID NO:
- 8), the LCDR2 is the polypeptide consisting of the amino acid sequence of GASSRAT (SEQ ID NO:
- 9), the LCDR3 is the polypeptide consisting of the amino acid sequence of QQYGSSPLT (SEQ ID NO:
- 10), the HCDR1 is the polypeptide consisting of the amino acid sequence of GFAFSSYGMH (SEQ ID NO:
- 2), the HCDR2 is the polypeptide consisting of the amino acid sequence of VIWYDGSNKYYADSVRG (SEQ ID NO:
- 3), and the HCDR3 is the polypeptide consisting of the amino acid sequence of DHYGSGVHHYFYYGLDV (SEQ ID NO:
- 4).
Dependencies are inferred from the claim text.